AstraZeneca: Neoplasm Metastasis trials

The registry lists 60 Neoplasm Metastasis studies with AstraZeneca as lead sponsor. 6 are open to participants now and 23 have results posted.

Phase 1 25Phase 2 19Phase 3 19No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingNCT07647328Phase 3
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruitingNCT07205822Phase 3
• Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)RecruitingNCT07044336Phase 3
• AZD5305 hADME in Patients With Advanced Solid MalignanciesRecruitingNCT06713369Phase 1
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingNCT06103864Phase 3
• PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanRecruitingNCT05573893
• A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Active, not recruitingNCT05104866Phase 3Results posted
• A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating MutationsActive, not recruitingNCT04639219Phase 2Results posted
• A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results posted
• A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingNCT04214288Phase 2Results posted
• A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingNCT04035486Phase 3Results posted
• Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedNCT03162224Phase 1/2Results posted
• A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsActive, not recruitingNCT02671435Phase 1/2Results posted
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02087423Phase 2Results posted
• Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.CompletedNCT02000622Phase 3Results posted
• Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)CompletedNCT01974752Phase 3Results posted
• Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCActive, not recruitingNCT01933932Phase 3Results posted
• Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT01809210Phase 1Results posted
• AZD9291 First Time In Patients Ascending Dose StudyCompletedNCT01802632Phase 1/2Results posted
• Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.CompletedNCT01750281Phase 2Results posted
• Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerCompletedNCT01605916Phase 1Results posted
• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedNCT01602380Phase 3Results posted
• Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric CancerTerminatedNCT01579578Phase 2Results posted
• Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast CancerCompletedNCT01446159Phase 2Results posted
• Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast CancerTerminatedNCT01151215Phase 2Results posted
• Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)CompletedNCT00900627Phase 1/2Results posted
• A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOXCompletedNCT00494221Phase 1/2Results posted
• First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT00344773Phase 2Results posted
• A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerCompletedNCT00055471Phase 2Results posted
• A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerActive, not recruitingNCT06792695Phase 2
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Active, not recruitingNCT05374512Phase 3
• Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT05348577Phase 3
• Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingNCT05261399Phase 3
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
• A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCActive, not recruitingNCT04995523Phase 1/2
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingNCT04964934Phase 3
• Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active, not recruitingNCT04784715Phase 3
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingNCT04711252Phase 3
• A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerCompletedNCT04087174Phase 1
• Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in BelgiumCompletedNCT03761901
• A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate CancerCompletedNCT02991911Phase 1
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
• Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneCompletedNCT02027961Phase 1
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced CancerCompletedNCT01352884Phase 1
• An Open Label Prostate Cancer Study in Japanese PatientsCompletedNCT01351688Phase 1
• Open Label Prostate Cancer StudyCompletedNCT01162395Phase 1
• Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.CompletedNCT01003158Phase 1
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursActive, not recruitingNCT00750841Phase 1
• Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid TumoursCompletedNCT00750425Phase 1
• Depiction of Prostate Cancer Treatment Alternatives in GreeceCompletedNCT00733213
• Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid TumoursCompletedNCT00710268Phase 1
• Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerCompletedNCT00707707Phase 1
• Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic TumoursCompletedNCT00633269Phase 1
• Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid TumoursCompletedNCT00621725Phase 1
• Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic TumorsCompletedNCT00503412Phase 1
• Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver MetastasesCompletedNCT00501605Phase 1
• A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast CancerCompletedNCT00241449Phase 3
• Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)SuspendedNCT00065572Phase 2
• Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.TerminatedNCT00065117Phase 2
• Iressa Expanded Access Program (EAP)CompletedNCT00034879Phase 3